Pharma Companies Have Increased MRP By 20-50 Per Cent Over The Past Six Months

Palanpur:  A sudden surge in the prices of life-saving drugs has left consumers reeling, as pharma companies have increased costs by 20-50 per cent over the past six months. Essential medications for hypertension, diabetes, cancer and common gastrointestinal ailments have reached new price highs, while the cost of antibiotics used in surgeries has nearly doubled.

Despite the applicability of the Essential Commodities Price Control Act in the state — which grants district magistrates authority to regulate and take action against price violations — there appears to be no enforcement against the profiteering of pharmaceutical companies.

Social activist Subhash Sharma highlighted shocking discrepancies in drug pricing. For instance, Pantoprazole-40 mg, prescribed for acidity, has an MRP of Rs 130 for a strip of 10 tablets, while its actual cost price is just Rs 20. This exposes profit margins exceeding 90 per cent, with some medications reportedly yielding profits of 1,000 per cent to 1,500 per cent for retailers. “This is only one example,” Sharma said, pointing out that similar price gouging affects hundreds of

In the absence of stringent checks, companies print exorbitant maximum retail prices (MRPs) on generic medicines, forcing poor patients to pay unjustified amounts. Many accuse administrative bodies and vigilance agencies of turning a blind eye, enabling pharmaceutical companies to exploit consumers.

A senior official from the state Drug Control Department admitted that state authorities have limited powers in this matter. “The Government of India has allowed pharma companies to print MRPs on all drugs, and only the Central Drug Controller can intervene,” the official stated.

Related Posts

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

New Delhi:  The National Pharmaceutical Pricing Authority (NPPA) has notified retail price of 42 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including anti hypertensive,…

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

New Delhi– In a landmark development for global child health, the World Health Organization (WHO) has granted prequalification to Coartem® Baby (artemether-lumefantrine), the first and only antimalarial medicine specifically developed…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

Laughing all the Way to Health with Sir Ganga Ram Hospital

Laughing all the Way to Health with Sir Ganga Ram Hospital

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop